公开(公告)号：US08946443B2

公开(公告)日：2015-02-03

申请号：US13634678

申请日：2011-03-14

申请人： Tsutomu Nagata ,  Jun Kobayashi ,  Yoshiyuki Onishi ,  Masamichi Kishida ,  Kengo Noguchi

发明人： Tsutomu Nagata ,  Jun Kobayashi ,  Yoshiyuki Onishi ,  Masamichi Kishida ,  Kengo Noguchi

IPC分类号： C07D233/64 ,  C07D401/04 ,  A61K31/4439 ,  C07D409/04 ,  A61K31/4178 ,  C07D417/04 ,  A61K31/427 ,  C07D403/04 ,  A61K31/506 ,  A61K31/4709 ,  C07D405/10 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P29/00 ,  A61P35/00 ,  A61P25/00 ,  A61P13/12 ,  A61P3/10 ,  A61P9/12 ,  A61P11/00 ,  A61P1/16 ,  A61P27/02 ,  A61P35/04 ,  A61K31/4164

CPC分类号： A61K31/4164 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/506 ,  C07D233/64 ,  C07D401/04

摘要： A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

摘要翻译： 由以下通式（I）表示的化合物或其药学上可接受的盐，其中R 1表示可以被选自取代基组A中的一至三个基团取代的C1至C6烷基等（取代基组A： 羟基，卤代基，氰基，硝基，氨基，羧基，C1〜C3烷基等）; R2，R3和R8各自独立地表示氢原子或C1〜C3烷基; R4，R5，R6，R7，R9和R10各自独立地表示氢原子等; R11表示氢原子等，具有TAFIa酶抑制活性，可用作心肌梗死，心绞痛，急性冠状动脉综合征，脑梗塞，深静脉血栓形成，肺栓塞等的治疗药物。

公开(公告)号：US20130035337A1

公开(公告)日：2013-02-07

申请号：US13418796

申请日：2012-03-13

申请人： Kousei Shimada ,  Yoshiyuki Onishi ,  Makoto Mori ,  Eri Tokumaru

发明人： Kousei Shimada ,  Yoshiyuki Onishi ,  Makoto Mori ,  Eri Tokumaru

IPC分类号： A61K31/4184 ,  C07D471/02 ,  A61K31/437 ,  C07D401/12 ,  A61K31/4439 ,  C07D413/12 ,  A61K31/5377 ,  C07D405/12 ,  A61P3/10 ,  A61P3/06 ,  A61P29/00 ,  A61P35/00 ,  A61P3/00 ,  A61P9/12 ,  A61P1/16 ,  A61P9/10 ,  A61P19/10 ,  A61P25/28 ,  A61P19/06 ,  A61P17/10 ,  A61P17/02 ,  A61P17/06 ,  A61P17/00 ,  A61P37/08 ,  A61P11/06 ,  A61P1/04 ,  A61P9/00 ,  A61P37/00 ,  A61P1/18 ,  A61P35/02 ,  A61P27/04 ,  C07D235/12

CPC分类号： C07D213/82 ,  C07D277/20 ,  C07D277/56 ,  C07D295/14 ,  C07D333/38 ,  C07D417/12

摘要： The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ.A compound having the general formula (I): wherein R1 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; Q represents a group represented by the formula ═CH— or a nitrogen atom; and Substituent Group a represents a halogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, and the like, or a pharmacologically acceptable salt thereof.

摘要翻译： 本发明涉及一种新的稠合双环杂芳基衍生物或其药理学上可接受的盐，其具有优异的降血糖作用或治疗和/或预防碳水化合物或脂质代谢紊乱或由过氧化物酶体增殖物激活受体介导的疾病 （PPAR）γ。 具有通式（I）的化合物：其中R1表示C1-C6烷基，可以被1至5个独立地选自取代基组a的基团取代的C6-C10芳基等; R2表示C1-C6烷基; R3表示可以被1至5个独立地选自取代基组a的基团取代的C 6 -C 10芳基等; Q表示由式= CH-或氮原子表示的基团; 和取代基组a表示卤素原子，C1-C6烷基，C1-C6羟烷基等，或其药理学上可接受的盐。

公开(公告)号：US20130012532A1

公开(公告)日：2013-01-10

申请号：US13634678

申请日：2011-03-14

申请人： Tsutomu Nagata ,  Jun Kobayashi ,  Yoshiyuki Onishi ,  Masamichi Kishida ,  Kengo Noguchi

发明人： Tsutomu Nagata ,  Jun Kobayashi ,  Yoshiyuki Onishi ,  Masamichi Kishida ,  Kengo Noguchi

IPC分类号： C07D233/64 ,  C07D401/04 ,  A61K31/4439 ,  C07D409/04 ,  A61K31/4178 ,  C07D417/04 ,  A61K31/427 ,  C07D403/04 ,  A61K31/506 ,  A61K31/4709 ,  C07D405/10 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P29/00 ,  A61P35/00 ,  A61P25/00 ,  A61P13/12 ,  A61P3/10 ,  A61P9/12 ,  A61P11/00 ,  A61P1/16 ,  A61P27/02 ,  A61P35/04 ,  A61K31/4164

CPC分类号： A61K31/4164 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/506 ,  C07D233/64 ,  C07D401/04

摘要： A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

公开(公告)号：US20100048564A1

公开(公告)日：2010-02-25

申请号：US12573625

申请日：2009-10-05

申请人： Kousei SHIMADA ,  Yoshiyuki ONISHI ,  Makoto MORI ,  Eri TOKUMARU

发明人： Kousei SHIMADA ,  Yoshiyuki ONISHI ,  Makoto MORI ,  Eri TOKUMARU

IPC分类号： A61K31/5377 ,  C07D235/12 ,  A61K31/4184 ,  C07D471/02 ,  A61K31/437 ,  C07D401/02 ,  A61K31/4439 ,  C07D413/02 ,  A61P3/10 ,  A61P29/00 ,  A61P35/00 ,  A61P9/00

CPC分类号： C07D213/82 ,  C07D277/20 ,  C07D277/56 ,  C07D295/14 ,  C07D333/38 ,  C07D417/12

摘要： The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ.A compound having the general formula (I): wherein R1 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; Q represents a group represented by the formula ═CH— or a nitrogen atom; and Substituent Group a represents a halogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, and the like, or a pharmacologically acceptable salt thereof.

摘要翻译： 本发明涉及一种新的稠合双环杂芳基衍生物或其药理学上可接受的盐，其具有优异的降血糖作用或治疗和/或预防碳水化合物或脂质代谢紊乱或由过氧化物酶体增殖物激活受体介导的疾病 （PPAR）γ。 具有通式（I）的化合物：其中R1表示C1-C6烷基，可以被1至5个独立地选自取代基组a的基团取代的C6-C10芳基等; R2表示C1-C6烷基; R3表示可以被1至5个独立地选自取代基组a的基团取代的C 6 -C 10芳基等; Q表示由式= CH-或氮原子表示的基团; 和取代基组a表示卤素原子，C1-C6烷基，C1-C6羟烷基等，或其药理学上可接受的盐。

公开(公告)号：US4757185A

公开(公告)日：1988-07-12

申请号：US42702

申请日：1987-04-27

申请人： Yoshiyuki Onishi

发明人： Yoshiyuki Onishi

IPC分类号： G06K17/00 ,  G06Q20/40 ,  G06Q40/00 ,  G06Q40/02 ,  G07C9/00 ,  G07D9/00 ,  G07F7/10 ,  G07F7/12 ,  G06K5/00

CPC分类号： G07F7/1008 ,  G06Q20/341 ,  G07C9/00111 ,  G07F7/084 ,  G07F7/1025

摘要： An automatic cash transaction apparatus includes a circuit for performing signal reception and transmission with a card carried by a user through the medium of electromagnetic wave. When a number set in the card and received by the apparatus is authorized one, the user is allowed to input the type of transaction desired by the user, cipher number and other data as required through key manipulation, whereby the manual handling of the card is made unnecessary.

摘要翻译： 自动现金交易装置包括用于通过电磁波介质执行用户携带的卡的信号接收和发送的电路。 当设置在卡中并由设备接收的号码被授权时，允许用户通过按键操作输入用户需要的交易类型，密码等数据，由此卡的手动处理是 不必要了